Two treatment methods for advanced prostate cancer

Categories: Spring 2024

dreamstime page 10A l 185358114A recent phase II trial compared two treatments for advanced prostate cancer. One treatment used lutetium-177 [177Lu] Lu-PSMA- 617, and the other used cabazitaxel. Both treatments were given to men whose cancer had spread after receiving docetaxel.

The study looked at how long the participants lived and updated the analysis of certain imaging tests. Some men were excluded from the study because their cancer did not show up well on these tests.

Researchers enrolled 291 men in the study, but only 200 met the criteria for treatment. These men were randomly assigned to receive either [177Lu] Lu-PSMA-617 or cabazitaxel. After about 36 months, they found that a similar number of men had died in both groups. The two treatments had no significant difference in how long men lived. The study also showed that men with certain characteristics, like low PSMA levels or specific results on imaging tests, tended to have shorter survival times.

In conclusion, the study suggests that [177Lu] Lu-PSMA-617 can be a good option for treating advanced prostate cancer, similar to cabazitaxel as fewer grade ≥ 3 adverse effects were observed with [177Lu] Lu-PSMA-617. However, certain characteristics of the cancer might affect how well these treatments work for individual patients.

The Lancet, Oncology. Jan. 2024. Volume 25 Issue 1, pp 99-107.




Subscribe to Quest

"*" indicates required fields


This email address is only for subscribing or unsubscribing to or from Quest. Dr. Catalona cannot respond to questions concerning your Personal Health Information (PHI) that could identify you as an individual. This is a "cyber-security measure" for your protection that will help prevent anyone from legally or illegally accessing your personal health information.

Delivery Method (How do you want to receive your Quest publication?)*